BRD4 antagonist-based therapy exerts lethal activity against FLT3 mutation expressing AML cells resistant to FLT3 tyrosine kinase inhibitors

被引：1
|
作者：
Rodriguez, Melissa [1 ]
Fiskus, Warren [1 ]
Sharma, Sunil [2 ]
Qi, Jun [3 ]
Schaub, Leasha J. [1 ]
Shah, Bhavin [1 ]
Devaraj, Santhana G. T. [1 ]
Liu, Ka [1 ]
Iyer, Swaminathan [1 ]
Bradner, James E. [3 ]
Bhalla, Kapil N. [1 ]
机构：
[1] Houston Methodist Res Inst, Houston, TX USA
[2] Huntsman Canc Inst, Salt Lake City, UT USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1721
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1721
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A comparison of the mutational landscapes between FLT3 tyrosine kinase inhibitor-resistant and parental AML cells based on whole transcriptomic sequencing
    Goktas, Nisa Nur
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 (04) : 497 - 498
  • [42] Sorafenib potently inhibits ETV6-PDGFRβ and FLT3 mutants, and shows activity against FLT3 mutants that are resistant to other small molecule inhibitors.
    Lierman, Els
    Lahortiga, Idoya
    Van Miegroet, Helen
    Mentens, Nicole
    Marynen, Peter
    Cools, Jan
    BLOOD, 2006, 108 (11) : 564A - 564A
  • [43] The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations
    Zhang, Weiguo
    Borthakur, Gautam
    Gao, Chen
    Chen, Ye
    Mu, Hong
    Ruvolo, Vivian R.
    Nomoto, Kenichi
    Zhao, Nanding
    Konopleva, Marina
    Andreeff, Michael
    CANCER RESEARCH, 2016, 76 (06) : 1528 - 1537
  • [44] Activation of protein phosphatase 2A in FLT3+acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
    Smith, Amanda M.
    Dun, Matthew D.
    Lee, Erwin M.
    Harrison, Celeste
    Kahl, Richard
    Flanagan, Hayley
    Panicker, Nikita
    Mashkani, Baratali
    Don, Anthony S.
    Morris, Jonathan
    Toop, Hamish
    Lock, Richard B.
    Powell, Jason A.
    Thomas, Daniel
    Guthridge, Mark A.
    Moore, Andrew
    Ashman, Leonie K.
    Skelding, Kathryn A.
    Enjeti, Anoop
    Verrills, Nicole M.
    ONCOTARGET, 2016, 7 (30) : 47465 - 47478
  • [45] CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib
    Jetani, Hardikkumar
    Garcia-Cadenas, Irene
    Nerreter, Thomas
    Thomas, Simone
    Rydzek, Julian
    Briones Meijide, Javier
    Bonig, Halvard
    Herr, Wolfgang
    Sierra, Jordi
    Einsele, Hermann
    Hudecek, Michael
    LEUKEMIA, 2018, 32 (05) : 1168 - 1179
  • [46] Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors
    Chang, Yu-Ting
    Hernandez, Daniela
    Alonso, Salvador
    Gao, Minling
    Su, Meng
    Ghiaur, Gabriel
    Levis, Mark J.
    Jones, Richard J.
    BLOOD ADVANCES, 2019, 3 (06) : 908 - 916
  • [47] SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells
    Yao Guo
    Yun Chen
    Xuesong Xu
    Xueqi Fu
    Zhizhuang Joe Zhao
    Journal of Hematology & Oncology, 5
  • [48] Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor
    K-F Tse
    J Allebach
    M Levis
    BD Smith
    FD Bohmer
    D Small
    Leukemia, 2002, 16 : 2027 - 2036
  • [49] SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells
    Guo, Yao
    Chen, Yun
    Xu, Xuesong
    Fu, Xueqi
    Zhao, Zhizhuang Joe
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
  • [50] Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor
    Tse, KF
    Allebach, J
    Levis, M
    Smith, BD
    Bohmer, FD
    Small, D
    LEUKEMIA, 2002, 16 (10) : 2027 - 2036
12345